Bevnexxa 400mg injection

• Cancer of colon and rectum
• Ovarian cancer
• Cervical cancer
• Kidney cancer
• Brain tumor
• Non-small cell lung cancer

Bevnexxa 400mg injection may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Nosebleeds
• Headache
• High blood pressure
• Inflammation of the nose
• Protein in urine
• Taste change
• Dry skin
• Hemorrhage
• Increased lacrimation
• Back pain
• Exfoliative dermatitis

Contact the doctor immediately in case of any severe or unusual side effects.

• Bevnexxa 400mg is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given intravenously by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  
  

Bevnexxa 400mg injection is an anti-angiogenic medication with Bevacizumab as an active ingredient. It works by blocking a specific protein known as vascular endothelial growth factor (VEGF). By blocking the action of specific protein it stops the formation of blood vessels that bring oxygen and nutrients to cancerous cells. Thereby, stop the growth & multiplication of cancer cells & slow down the progression of disease.

• Emerson, M. V., Lauer, A. K., Flaxel, C. J., Wilson, D. J., Francis, P. J., Stout, J. T., ... & Klein, M. L. (2007). Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina, 27(4), 439-444. https://pubmed.ncbi.nlm.nih.gov/17420695/
• Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., ... & Liang, S. X. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365(26), 2473-2483. https://ohiostate.elsevierpure.com/en/publications/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-/
• Bergsland, E., & Dickler, M. N. (2004). Maximizing the potential of bevacizumab in cancer treatment. The Oncologist, 9(S1), 36-42. https://pubmed.ncbi.nlm.nih.gov/15178814/
• Gil-Gil, M. J., Mesia, C., Rey, M., & Bruna, J. (2013). Bevacizumab for the treatment of glioblastoma. Clinical Medicine Insights: Oncology, 7, CMO-S8503. https://pmc.ncbi.nlm.nih.gov/articles/PMC3682734/
• Falk, A. T., Barrière, J., François, E., & Follana, P. (2015). Bevacizumab: a dose review. Critical reviews in oncology/hematology, 94(3), 311-322. https://pubmed.ncbi.nlm.nih.gov/25703583/